First licensed treatment for hidradenitis suppurativa

HS is a painful, chronic systemic inflammatory disorder, characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.
‘The approval of Humira to treat moderate to severe HS is a major step forward in supporting patients with this distressing and life-changing condition,’ said Dr David Fitzgerald, consultant dermatologist at Salford Royal NHS Foundation Trust. ‘Patients with HS can experience immense pain and the condition often dramatically affects their psychological wellbeing and quality of life.’
The benefits and risks of long-term treatment should be regularly evaluated and if treatment is interrupted, Humira may be reintroduced at the maintenance dose of 40mg per week.